Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics raises 2025 BRIUMVI revenue guidance to $570 million to $575 million

Positive Impact 4 of 5 guidance Written later

TG Therapeutics reported second quarter 2025 total revenue of $141.1 million, up from $73.5 million a year earlier, and net income of $28.2 million, compared with $6.9 million. The company raised its full-year 2025 BRIUMVI U.S. net revenue target to $570 million to $575 million from $560 million, and its total global revenue target to approximately $585 million from $575 million.

Key points

  • Q2 2025 BRIUMVI U.S. net product revenue was $138.8 million, up 91% from the same period last year.
  • Full-year 2025 BRIUMVI U.S. net revenue target raised to $570 million to $575 million, from $560 million.
  • Full-year 2025 total global revenue target raised to approximately $585 million, from $575 million.
  • Cash, cash equivalents and investment securities were $278.9 million as of June 30, 2025.

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECAug 4, 2025, 7:35 AM ET
Accession number0001437749-25-024480

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.